Analysts Issue Forecasts for Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Management issued their FY2029 EPS estimates for shares of Moderna in a research note issued on Monday, January 13th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of $22.02 per share for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share.

Several other equities analysts also recently weighed in on the stock. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Berenberg Bank began coverage on shares of Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 target price for the company. Finally, Bank of America restated an “underperform” rating and set a $41.00 target price on shares of Moderna in a research report on Tuesday, December 10th. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.83.

Moderna Trading Down 2.0 %

Shares of Moderna stock opened at $34.46 on Wednesday. Moderna has a 1-year low of $31.94 and a 1-year high of $170.47. The company’s fifty day simple moving average is $41.78 and its 200-day simple moving average is $67.79. The stock has a market capitalization of $13.26 billion, a PE ratio of -5.92 and a beta of 1.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.39) earnings per share.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the 2nd quarter valued at $26,000. Plato Investment Management Ltd lifted its position in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after acquiring an additional 288 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Moderna in the 2nd quarter worth approximately $75,000. Blue Trust Inc. boosted its holdings in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the period. Finally, Larson Financial Group LLC grew its position in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. 15.70% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.